Ruxolitinib Phosphate

Name: Ruxolitinib Phosphate
Brand: Selleck Chemicals
SKU: S5243
Rating: 5 (123 reviews)

For research use only.

Catalog No.S5243 Synonyms: INCB018424, INC424

123 publications

Ruxolitinib Phosphate Chemical Structure

CAS No. 1092939-17-7

Ruxolitinib Phosphate (INCB018424, INC424) is the phosphate salt form of Ruxolitinib. Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.

Selleck's Ruxolitinib Phosphate has been cited by 123 publications

Sci Immunol, 2021, 6(59)eabi9007

PubMed: 34010142 ( click the link to review the publication )

J Cell Biol, 2021, 220(9)e202004114

PubMed: 34287648 ( click the link to review the publication )

Leukemia, 2021, 10.1038/s41375-021-01326-x

PubMed: 34193976 ( click the link to review the publication )

Cancer Res, 2021, canres.3761.2020

PubMed: 34215619 ( click the link to review the publication )

Cancer Lett, 2021, 510:37-47

PubMed: 33872695 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3780

PubMed: 34359681 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01270-8

PubMed: 33658640 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(10):14234-14257

PubMed: 34016786 ( click the link to review the publication )

Neoplasia, 2021, 23(2):270-279

PubMed: 33465556 ( click the link to review the publication )

J Immunol, 2021, ji2000569

PubMed: 33431658 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16684

PubMed: 34322995 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1194

PubMed: 33530480 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(7)3530

PubMed: 33805426 ( click the link to review the publication )

Microorganisms, 2021, 9(3)564

PubMed: 33803310 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10093

PubMed: 33980892 ( click the link to review the publication )

J Pathol Clin Res, 2021, 10.1002/cjp2.211

PubMed: 33890726 ( click the link to review the publication )

Eur J Pharmacol, 2021, 902:174121

PubMed: 33901462 ( click the link to review the publication )

PLoS One, 2021, 16(3):e0248175

PubMed: 33770100 ( click the link to review the publication )

J Gen Virol, 2021, 102(3)

PubMed: 33416466 ( click the link to review the publication )

Exp Hematol, 2021, S0301-472X(21)00244-7

PubMed: 34182006 ( click the link to review the publication )

Viruses, 2021, 13(7)1406

PubMed: 34372612 ( click the link to review the publication )

Viruses, 2021, 13(2)154

PubMed: 33494454 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabb3555

PubMed: 33568470 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab035

PubMed: 33517393 ( click the link to review the publication )
Oncotarget, 2021, 12(9):878-890

PubMed: 33953842 ( click the link to review the publication )

Blood, 2020, 12;blood.2020006075

PubMed: 32530039 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4886

PubMed: 32985500 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-01077-1

PubMed: 33149267 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(26):15047-15054

PubMed: 32532922 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 29;201918307

PubMed: 32471953 ( click the link to review the publication )

Mol Ther, 2020, S1525-0016(20)30609-2

PubMed: 33352107 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1603

PubMed: 32560455 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Comput Struct Biotechnol J, 2020, 18:3977-3986

PubMed: 33335694 ( click the link to review the publication )

Cell Death Discov, 2020, 2;6:42

PubMed: 32528731 ( click the link to review the publication )

Cancer Discov, 2020, 10(4):608-625

PubMed: 32046984 ( click the link to review the publication )

Aging (Albany NY), 2020, 12

PubMed: 33146632 ( click the link to review the publication )

J Immunol, 2020, 1;204(9):2492-2502

PubMed: 32213567 ( click the link to review the publication )

J Immunol, 2020, 205(10):2629-2639

PubMed: 33067379 ( click the link to review the publication )

J Cell Physiol, 2020, 235(5):4605-4617

PubMed: 31663116 ( click the link to review the publication )

mSphere, 2020, 5(6)e00449-20

PubMed: 33328346 ( click the link to review the publication )

J Virol, 2020, 15 pii: JVI

PubMed: 32295912 ( click the link to review the publication )

J Virol, 2020, JVI.01413-20

PubMed: 33177205 ( click the link to review the publication )

J Virol, 2020, JVI.01136-20

PubMed: 33328306 ( click the link to review the publication )

J Virol, 2020, 17;94(3) pii: e01233-19

PubMed: 31694940 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(9):e0008610

PubMed: 32931521 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16132

PubMed: 33274592 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2020, 10.1165/rcmb.2019-0431OC

PubMed: 33052714 ( click the link to review the publication )
Phytomedicine, 2020, 80:153394

PubMed: 33130472 ( click the link to review the publication )

Virology, 2020, 551:75-83

PubMed: 32829915 ( click the link to review the publication )

Exp Eye Res, 2020, S0014-4835(20)30611-4

PubMed: 33171193 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15700

PubMed: 32761753 ( click the link to review the publication )

BMC Mol Cell Biol, 2020, 21(1):74

PubMed: 33126846 ( click the link to review the publication )

Biochem Biophys Rep, 2020, 24:100832

PubMed: 33102814 ( click the link to review the publication )

Viruses, 2020, 12(10)E1141

PubMed: 33050000 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Blood Adv, 2020, 4(20):5297-5310

PubMed: 33108458 ( click the link to review the publication )

Oncogene, 2020, 39(31):5323-5337

PubMed: 32572159 ( click the link to review the publication )

J Biol Chem, 2020, jbc.AC120.13788

PubMed: 32587093 ( click the link to review the publication )

Blood, 2019, 26;134(26):2388-2398

PubMed: 31697804 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Front Immunol, 2019, 10:1659

PubMed: 31396213 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):46

PubMed: 31101051 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31262043 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(32):11952-11959

PubMed: 31248987 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(12):3776-3785

PubMed: 31503282 ( click the link to review the publication )

Inflamm Res, 2019, 101007/s00011-019-01293-1

PubMed: 31654094 ( click the link to review the publication )

PLoS One, 2019, 14(7):e0220026

PubMed: 31318944 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Zhonghua Xue Ye Xue Za Zhi, 2019, 40(12):1003-1007

PubMed: 32023730 ( click the link to review the publication )

Brain, 2018, 141(6):1609-1621

PubMed: 29741608 ( click the link to review the publication )
Cancer Res, 2018, 78(1):75-87

PubMed: 29122767 ( click the link to review the publication )

EBioMedicine, 2018, 36:367-375

PubMed: 30269996 ( click the link to review the publication )

Cancer Lett, 2018, 412:194-207

PubMed: 29074425 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Oncoimmunology, 2018,

PubMed: 29872580 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

J Immunol, 2018, 201(8):2462-2471

PubMed: 30209193 ( click the link to review the publication )

J Immunol, 2018, 201(8):2392-2402

PubMed: 30224514 ( click the link to review the publication )

mSphere, 2018, 3(1)e00567-17

PubMed: 29299535 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Clin Breast Cancer, 2018, 18(5):e1205-e1215

PubMed: 29933930 ( click the link to review the publication )

Leuk Res, 2018, 74:57-63

PubMed: 30300821 ( click the link to review the publication )

JCO Precis Oncol, 2018, 2018

PubMed: 30079384 ( click the link to review the publication )

Immunity, 2017, 21;46(2):220-232

PubMed: 28228280 ( click the link to review the publication )

Elife, 2017, 6e27210

PubMed: 28741471 ( click the link to review the publication )

Clin Epigenetics, 2017, 9:4

PubMed: 28149332 ( click the link to review the publication )

Arch Toxicol, 2017, 91(10):3385-3402

PubMed: 28365849 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Clin Exp Allergy, 2017, 47(1):71-84

PubMed: 27910206 ( click the link to review the publication )

mSphere, 2017, 2(3)e00234-17

PubMed: 28680969 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(10)e00771-17

PubMed: 28717041 ( click the link to review the publication )

Sci Rep, 2017, 7:43441

PubMed: 28240310 ( click the link to review the publication )

J Biol Chem, 2017, 292(20):8136-8148

PubMed: 28270510 ( click the link to review the publication )

Cytokine, 2017, 90:73-79

PubMed: 27816795 ( click the link to review the publication )
Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

Oncotarget, 2017, 8(53):91516-91529

PubMed: 29207662 ( click the link to review the publication )

Cell, 2017, 168(5):890-903

PubMed: 28162770 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89923-89938

PubMed: 29163799 ( click the link to review the publication )

Cell, 2017, 168(6):1053-1064

PubMed: 28283061 ( click the link to review the publication )

Cancer Res, 2016, 76(4):773-86

PubMed: 26676752 ( click the link to review the publication )

Oncogene, 2016, 35(46):6001-6014

PubMed: 27086927 ( click the link to review the publication )

Front Oncol, 2016, 6:142

PubMed: 27379204 ( click the link to review the publication )

J Leukoc Biol, 2016, 100(1):213-22

PubMed: 27034404 ( click the link to review the publication )

Sci Rep, 2016, 6:27326

PubMed: 27251437 ( click the link to review the publication )

J Biol Chem, 2016, 291(49):25656-25666

PubMed: 27780867 ( click the link to review the publication )

Parasite Immunol, 2016, 38(11):678-687

PubMed: 27543848 ( click the link to review the publication )

Oncotarget, 2016, 7(38):61601-61618

PubMed: 27533247 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59260-59272

PubMed: 27449287 ( click the link to review the publication )

Oncotarget, 2016, 7(14):17290-300

PubMed: 26981780 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47465-47478

PubMed: 27329844 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Cell Rep, 2015, 11(1):98-110

PubMed: 25843712 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

Sci Rep, 2015, 5:7820

PubMed: 25592282 ( click the link to review the publication )

J Interferon Cytokine Res, 2015, 35(9):698-709

PubMed: 26090579 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40141-57

PubMed: 26472029 ( click the link to review the publication )

J Allergy Clin Immunol, 2015, 135(2):551-3

PubMed: 25662309 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26431376 ( click the link to review the publication )
Oncotarget, 2014, 5(16):6801-15

PubMed: 25149535 ( click the link to review the publication )

Blood, 2013, 15;122(7):1192-202

PubMed: 23770777 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74257

PubMed: 24066127 ( click the link to review the publication )

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description

Targets

JAK2 ^[1] (Cell-free assay)	JAK1 ^[1] (Cell-free assay)
2.8 nM	3.3 nM

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Sf21	NYPaWZZCTnWwY4Tpc44h[XO\|YYm=		MYWxJIhz	MVTJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJia3nuZZNmKGSxbXHpckBmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczD1d4lv\yCHUVXESXBGT0S\RlXXUGUh[XNic4Xid5Rz[XSnIHHmeIVzKDFiaIKgZpkhUFSURjDhd5NigSxiSVO1NF0xNjByMklOwG0>	MkXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OUG0NFIoRjJ{NUmxOFAzRC:jPh?=
Sf21	MVPGeY5kfGmxbjDhd5NigQ>?		M3:2SVEhcHJ?	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGpCUzFia3nuZZNmKGSxbXHpckBmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczD1d4lv\yCHUVXESXBGT0S\RlXXUGUh[XNic4Xid5Rz[XSnIHHmeIVzKDFiaIKgZpkhUFSURjDhd5NigSxiSVO1NF0xNjByM{ROwG0>	NEHoTng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW5NVQxOid-MkK1PVE1ODJ:L3G+
Sf21	NV7HZ5RTTnWwY4Tpc44h[XO\|YYm=		NX;zb\|c4OSCqch?=	M3Tab2lvcGmkaYTpc44hd2ZiaIXtZY4hXFmNMjDrbY5ie2ViZH;tZYlvKGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzJJV{cW6pIFXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCKVGLGJIF{e2G7LDDJR\|UxRTBwMEG5{txO	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV7MUSwNkc,OjJ3OUG0NFI9N2F-
Sf21	NV3GdJhWTnWwY4Tpc44h[XO\|YYm=		NGnycFMyKGi{	Mmi4TY5pcWKrdHnvckBw\iCqdX3hckBLSUt\|IHvpcoF{\SCmb33hbY4h\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgeZNqdmdiRWHFSGVRTUeGWV\FW2xGKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KEiWUl[gZZN{[XluIFnDOVA:OC52MklOwG0>	NWnKWopGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PVE1ODJpPkKyOVkyPDB{PD;hQi=>
TF1	NFvVNlFHfW6ldHnvckBie3OjeR?=		MUWyNEBucW6\|	MnXWTY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMheHKrb4KgeI8hTVCRLXnu[JVkfGmxbjDt[YF{fXKnZDDh[pRmeiB\|MDD0c{A1PSCvaX7zMEBGSzVyPUCuNFEz\|ryP	NFrWTZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[5PFA5PCd-MkK2PVgxQDR:L3G+
TF1	NEDT[IdHfW6ldHnvckBie3OjeR?=		M{nDelIxKG2rboO=	NYn6dGM{UW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNicILpc5IhfG9iSVy2MYlv\HWldHnvckBu\WG\|dYLl[EBi\nSncjCzNEB1dyB2NTDtbY5{NCCHQ{WwQVAvODJ2zszN	NILxSIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[5PFA5PCd-MkK2PVgxQDR:L3G+
SET2	MWjGeY5kfGmxbjDhd5NigQ>?			M3fTZ2lvcGmkaYTpc44hd2ZiSlHLNkBXPjF5RjDteZRidnRiaX6gbJVu[W5iU1XUNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iU2TBWFUheGixc4Doc5J6dGG2aX;uMEBKSzVyPUCuNFAyQDUQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MU[2NEc,OjNyNkG2OlA9N2F-
TF1	NE\keINHfW6ldHnvckBie3OjeR?=		M2PWSFMxKG2rboO=	NWLLZ4VqUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOzBibXnud{BqdiCycnXz[Y5k\SCxZjDoeY1idiC{ZXPvcYJqdmGwdDDFVG8tKEmFNUC9NE4xODZ6Nd88US=>	M{HGNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xOlYxLz5{M{C2NVY3ODxxYU6=
T-cells	MXjGeY5kfGmxbjDhd5NigQ>?			NYi0UmlDUW6qaXLpeIlwdiCxZjDKRWs{NzFiaX6gbJVu[W5iVDDj[YxteyCneIDy[ZN{cW6pIFPEN{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOi2\|dHnteYxifGWmIGPURXQ2[SCyaH;zdIhwenmuYYTpc44tKEmFNUC9NE4xOjQQvF2=	NVPtNpA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
T-cells	Mor2SpVv[3Srb36gZZN{[Xl?			MVvJcohq[mm2aX;uJI9nKEqDS{KvNUBqdiCqdX3hckBVKGOnbHzzJIV5eHKnc4PpcochS0R\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSV\O[4FudWFvc4TpcZVt[XSnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44tKEmFNUC9NE4xOzIQvF2=	NYfoWoVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
Sf9	MXHGeY5kfGmxbjDhd5NigQ>?		MYCxJIhz	MYHJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiKEiyPE0yOTN{KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKEWTRVTFVGVITFmIRWfMSUBieyC\|dXLzeJJifGViYX\0[ZIhOSCqcjDifUBJXFKIIHHzd4F6NCCNaU2wMlAxODIQvF2=	NYPBcXJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9	M3fUcGZ2dmO2aX;uJIF{e2G7		M3PVc\|EhcHJ?	NX2zU\|M4UW6qaXLpeIlwdiCxZjDoeY1idiCMQVuxJEg5OzdvMUG0Nkkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliSGTSSkBie3OjeTygT4k:OC5yMECy{txO	Mn;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ\|Nk[4OFg1RC:jPh?=
Sf9	NETJNHNHfW6ldHnvckBie3OjeR?=		M2DVTFEhcHJ?	NVfudpBbUW6qaXLpeIlwdiCxZjDoeY1idiCWWVuyJEg5PzNvMUG4O{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliSGTSSkBie3OjeTygT4k:OC5yMEC1{txO	NVXISYlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9	NUfjcZZWTnWwY4Tpc44h[XO\|YYm=		NGTlNGUyKGi{	MUXJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzNiKEe4NU0yOTJ2KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKEWTRVTFVGVITFmIRWfMSUBieyC\|dXLzeJJifGViYX\0[ZIhOSCqcjDifUBJXFKIIHHzd4F6NCCNaU2wMlAxOzMQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES4OEc,OjN4Nki0PFQ9N2F-
CD34+	MWXGeY5kfGmxbjDhd5NigQ>?		MVG0OUBucW6\|	NU\HW405UW6qaXLpeIlwdiCxZjDKRWszKGixbX;kbY1meiCrbjDoeY1idiCFREO0L{Bk\WyuczDzdIls\WRiaX70c{BpfW2jbjD3bI9t\SCkbH;v[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWStOUBxcG:\|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjC0OUBucW6\|IH\vcIxwf2WmIHL5JGVRVyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAyPSCvaX7zJIJ6KE[DQ2OgZY5idHm\|aYOsJGlEPTB;MD62O\|fPxE1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{WzN{c,OjR2MUe1N\|M9N2F-
BA/F3	NGDFRoJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3H6PFczKGi{cx?=	NY\4[mJ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKFSHTD3KRWsyKGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzKGeubzDhd5NigQ>?	NEj4bYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BA/F3	NHu5TpFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH\ROGc4OiCqcoO=	NEPHcldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXEWOLVrBT\|Ih[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIh\2yxIHHzd4F6	NIXiXYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
TALL-1	NHXVZpZHfW6ldHnvckBie3OjeR?=	NFXRSWQyKHWP	MWizJIhzew>?	NGLqSGxKdmirYnn0bY9vKG:oIFrBT\|MhcW5iaIXtZY4hXEGOTD2xJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSVytNkBqdmS3Y3XkJHNVSVR3IIDoc5NxcG:{eXzheIlwdiCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOyCqcoOg[o9tdG:5ZXSgZpkhUUxvMjDpcoR2[3Srb36gcYVie3W{ZXSgZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>?	NIT0cG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
OCL-AML5	MVrGeY5kfGmxbjDhd5NigQ>?	MYOxJJVO	MVizJIhzew>?	M{T6NGlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBQS0xvQV3MOUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFfNMWNUTiCrbnT1Z4VlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiMzDodpMh\m:ubH;3[YQh[nliR12tR3NHKGmwZIXjeIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7n	NYrMOXlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
CD34+	NEf3VY1HfW6ldHnvckBie3OjeR?=			M4PGVGlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBETDN2KzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3t[YRq[XSnZDDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;MD6wNFjPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
PBMC	MWrGeY5kfGmxbjDhd5NigQ>?			NFrhbo5KdmirYnn0bY9vKG:oIFrBT\|EhcW5iaIXtZY4hWEKPQzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLU[tbY5lfWOnZDDNR3AyKHOnY4LleIlwdixiSVO1NF0xNjB2zszN	NGGxZ5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyO\|QzOyd-Mk[5Nlc1OjN:L3G+
PBMC	NGPPS5NHfW6ldHnvckBie3OjeR?=			MoriTY5pcWKrdHnvckBKVC15LXnu[IN2\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBDVUNiY3XscJMh[nliZnzve{BkgXSxbXX0dpktKEmFNUC9NE41PDkQvF2=	M4jsXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUK3OFI{Lz5{NkmyO\|QzOzxxYU6=
Sf21	MYLGeY5kfGmxbjDhd5NigQ>?		Mn7MOlAhdWmwcx?=	Mn;VTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCMQVuyJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCXbHnnbJQuS0GJQVfBTWVVTEuHWWnUWmtFKHCqb4PwbI9zgWyjdHnvckBxemVvaX7jeYJifGWmIHLl[o9z\SC\|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IE[wJI1qdnNiYomgUGFPS0ViZHX0[YN1cW:wIH3leIhw\CxiSVO1NF0xNjByM988US=>	MlvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{ezOVkoRjJ5MUO3N\|U6RC:jPh?=
Sf21	NYTjW5JiTnWwY4Tpc44h[XO\|YYm=		NULZfJVIOSCqch?=	NFm4cGtKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFOteIVzdWmwYXygOmhqey22YXfn[YQhUkGNMjCoPFA5KHSxIHXu[EBidWmwbzDhZ4lleyliZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCrbjDwdoV{\W6lZTDv[kBCXFBiYomgWHIuTlKHVDDhd5NigSxiSVO1NF0xNjByNEJOwG0>	M1exO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUW1Nlg1Lz5{N{W1OVI5PDxxYU6=
BaF3	NH36Z5pHfW6ldHnvckBie3OjeR?=			M1fY[GlvcGmkaYTpc44hd2ZiSlHLNkBXPjF5RjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5MEBGSzVyPUCuNVg3\|ryP	MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NUWyPFQoRjJ5NUW1Nlg1RC:jPh?=
HEL 92.1.7	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2G2V\|Mh\GG7cx?=	NFfuZ2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGVCB7Mj6xMlch[2WubIOgZZN{\XO\|ZXSgZZMhfmmjYnzlJINmdGy\|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCZU2StNUBie3OjeTygTWM2OD1zND63{txO	MlzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NUWyPFQoRjJ5NUW1Nlg1RC:jPh?=
HCC827	MnvwSpVv[3Srb36gZZN{[Xl?	M1HBfFMxKHWP	M1e1ZVI1KGi{cx?=	M3npSWlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBo\W[rdHnubYIuemW\|aYP0ZY51KEiFQ{iyO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCC\N{C1JJNqfGViYYSgN\|AhfU1ibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KHenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NGSxdoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W1OVI5PCd-Mke1OVUzQDR:L3G+
HCC827	NHjiUoRHfW6ldHnvckBie3OjeR?=	NHfPbos{OCC3TR?=	NILwOZozPCCqcoO=	MlHMTY5pcWKrdHnvckBw\iCMQVuyJIlvKHerbHSteJlx\SCqdX3hckBJS0N6MkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDzbZRmKGG2IEOwJJVOKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUB4\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	NUXa[nFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1OVUzQDRpPkK3OVU2Ojh2PD;hQi=>
HEL	NWP3c2IySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEHVO3k1QCCqcoO=	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFUEBk\WyuczDoZZJjd3KrbnegTmFMOiCYNkG3SkBufXSjboSgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lk[y{txO	NXO3WIJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzVpPkK3O\|c1OTN3PD;hQi=>
K562	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn21OFghcHK\|	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOC5\|zszN	Ml[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxN\|UoRjJ5N{e0NVM2RC:jPh?=
MOLT4	MlHYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEjabJA1QCCqcoO=	M4HnfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zNT64{txO	NIPBV5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{PSd-Mke3O\|QyOzV:L3G+
NCI-H23	M3TzRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NYTOeIY5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGijcnLvdolv\yCNUlHTJGcyOkNibYX0ZY51KGG2	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEm0NEc,OjhyM{i5OFA9N2F-
NCI-H358	NUjHZpdySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MkDwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFM2QCClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJEKG23dHHueEBifA>?	NVW0OY9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g6PDBpPkK4NFM5QTRyPD;hQi=>
A673	NIHTNndyUFSVIHHzd4F6			Mly5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NEjE[3VyUFSVIHHzd4F6			M1jmSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NE[wfFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MVPxTHRUKGG\|c3H5			NXzQWlVZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NX\h[Y1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	M4TNV5FJXFNiYYPzZZk>			MojadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MlSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HeLa	NIXDVopHfW6ldHnvckBie3OjeR?=	NVvtO2JMOC5zIITvJFEhfU1?	MXWxJIhz	M2PUU2lvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNE4yKHSxIEGgeW0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	M1mz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkSzNVU5Lz5\|MEK0N\|E2QDxxYU6=
HeLa	NXn6[JVRTnWwY4Tpc44h[XO\|YYm=	MlLVNE4yKHSxIEGgeW0>	MnXSNUBpeg>?	M2HJeGlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGpCUzJicHjvd5Bpd3K7bHH0bY9vKGG2IECuNUB1dyBzIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	NH3KPGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK0N\|E2QCd-M{CyOFMyPTh:L3G+
Sf9	MnjlSpVv[3Srb36gZZN{[Xl?		NHT0SFMyKGi{	NGjF[GRKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgLFgzQCC2bzCxNVMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTBwMECyPO69VQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODh\|M{G1PEc,OzB6M{OxOVg9N2F-
Sf9	M2rWNWZ2dmO2aX;uJIF{e2G7		M3n0XVEhcHJ?	M4e2WmlvcGmkaYTpc44hd2ZiaIXtZY4hUkGNMTCoPFM4KHSxIEGxOFIhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIFXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVA:OC5yMEOz{txO	NUn3O\|N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C4N\|MyPThpPkOwPFM{OTV6PD;hQi=>
HEL	NWjKNGR1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYe0PEBpenN?	NEeyZWlUgW6ncnfpd5Rq[yCjboTpdJJwdGmoZYLheIl3\SCjY4Tpeol1gSCjZ3HpcpN1KEiHTDDj[YxteyCqYYLic5JqdmdiSlHLNkBXPjF5RjDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCrbjDwdoV{\W6lZTDv[kBUSUiDIHL5JG1VXCCjc4PhfUwhUUN3ME2wMlPPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlyMUKwPEc,OzB7MEGyNFg9N2F-
K562	NIT0WW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2XqSlQ5KGi{cx?=	M3vGXXN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIlvKHC{ZYPlcoNmKG:oIGPBTGEh[nliTWTUJIF{e2G7LDDJR\|UxRTFwMEROwG0>	MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
MOLT4	MlvSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4fOdlQ5KGi{cx?=	M3\GeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVUvQM7:TR?=	MnnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
HEL	NWj3OowzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUW0PEBpenN?	NHPk[opCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGVCClZXzsd{Bp[XKkb4LpcochUkGNMjDWOlE4TiCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OThwNt88US=>	MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
K562	MkfiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlHpOFghcHK\|	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MkOuNu69VQ>?	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
A549	M{GycWZ2dmO2aX;uJIF{e2G7	MmnjPFAhfG9iNECwJI5O	NUj0WpZSPiCqcoO=	M4PJeWlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBi[2W2eXygbIl{fG:wZTDIOEBt\X[nbDDheEA5OCC2bzC0NFAhdk1iYX\0[ZIhPiCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlyMUKwPEc,OzB7MEGyNFg9N2F-
A549	NEjhOoNHfW6ldHnvckBie3OjeR?=	M3LIelgxKHSxIESwNEBvVQ>?	M{HMR\|YhcHK\|	NVS5T2FUUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGlZYT5cEBpcXO2b37lJGg1KGyndnXsJIF1KDhyIITvJFQxOCCwTTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NWTJ[2loRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
A549	NILGN41HfW6ldHnvckBie3OjeR?=	NVjCO2JpQDBidH:gOFAxKG6P	NYDpZXprPiCqcoO=	M3rsWGlvcGmkaYTpc44hd2ZiSFTBR\|MhcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBi[2W2eXygbIl{fG:wZTDIOEBt\X[nbDDheEA5OCC2bzC0NFAhdk1iYX\0[ZIhPiCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NYjrNJNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
A549	M1jCO2Z2dmO2aX;uJIF{e2G7	NIm4TFQ5OCC2bzC0NFAhdk1?	MVS2JIhzew>?	MXLJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNmfHmuIHHsdIhiKHS3YoXsbY4hdGW4ZXygZZQhQDBidH:gOFAxKG6PIHHmeIVzKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MnrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
HEL	M1PhZmZ2dmO2aX;uJIF{e2G7	MYWxNFAhdWdxa3e=	M4rDXlUh\GG7cx?=	MVjEdpVoKGyndnXsJIlvKHS3bX;yJI9nKEKDTFKvZ{BvfSCvb4Xz[UB5\W6xZ4Lh[pRm\CC5aYToJGhGVCClZXzsd{BifCBzMECgcYcwc2dxZHH5MEBqeCCjZH3pcol{fGW{ZXSg[o9zKDViZHH5d{BidmRibXXhd5Vz\WRiMTDodkBxd3O2LXzhd5Qh\G:\|ZTDifUBNSy2PUz;NV{BidmGueYPpdy=>	Ml\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MEGyNFgoRjNyOUCxNlA5RC:jPh?=
Sf9	MnTmSpVv[3Srb36gZZN{[Xl?		M1ThPFMxKHOnY4O=	MXvJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiaHX4ZYhqe3SrZHnu[UB1[WepZXSgTmFMOiCMSEGgZ4F1[Wy7dHnjJIRwdWGrbjCoPFM2KHSxIEGxN\|IhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMhfXOrbnegWJlzPiCyZYD0bYRmKGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDNyIIPlZ5MhfW6mZYKgd4hic2mwZzDjc45lcXSrb36gcYVie3W{ZXSgZYZ1\XJiMTDodkAtKEmFNUC9NE4xODB4zszN	NIXoW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEm4NVU4QCd-M{C5PFE2Pzh:L3G+
Sf21	NY\4[mVVTnWwY4Tpc44h[XO\|YYm=		MV[xJIhz	NXOzOYl4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJIVxcXSxcHWteIFo\2WmIFrBT\|IhMDh{ODD0c{AyOTN{IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBqdnOnY4SgZ4VtdHNidYPpcochTVGHRFXQSWdFYU[HV1zFJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JIhwdW:pZX7lc5V{KHSrbXWtdoV{d2y4ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuNFAzQM7:TR?=	NUPWWGVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFE2PzhpPkOwPVgyPTd6PD;hQi=>
Sf9	M4rFVmZ2dmO2aX;uJIF{e2G7		MYCzNEB{\WO\|	MnTNTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIHjlfIFpcXO2aXTpcoUhfGGpZ3XkJGpCUzFiSlixJINifGGueYTpZ{Bld22jaX6gLFg2PCC2bzCxNVU1KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW\|aX7nJHR6ejZicHXweIll\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB\|MDDz[YN{KHWwZHXyJJNp[WurbnegZ49v\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGgbJIhNCCLQ{WwQVAvODB2zszN	M17SdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixOVc5Lz5\|MEm4NVU4QDxxYU6=
Sf9	M{TwVGZ2dmO2aX;uJIF{e2G7			NUG2RXVVSmmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIHjlfIFpcXO2aXTpcoUhfGGpZ3XkJGpCUzJiSlixJINifGGueYTpZ{Bld22jaX6gLFg{PSC2bzCxNVMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTpd5Nw[2mjdHnvckBkd26\|dHHueEBjgSC\|dYLmZYNmKHCuYYPtc44hemW\|b37hcoNmKGG\|c3H5MEBM\D1yLkCyPFLPxE1?	NWDQ[nQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFE2PzhpPkOwPVgyPTd6PD;hQi=>
Sf9	Mn3CSpVv[3Srb36gZZN{[Xl?		M1jnSFMxKHOnY4O=	MoPOTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCFLYTldo1qdmGuIHjlfIFpcXO2aXTpcoUhfGGpZ3XkJGpCUzNiSlixJINifGGueYTpZ{Bld22jaX6gLFgyOSC2bzCxNVI1KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW\|aX7nJHR6ejZicHXweIll\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB\|MDDz[YN{KHWwZHXyJJNp[WurbnegZ49v\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGgbJIhNCCLQ{WwQVAvODVzzszN	NHvyZnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEm4NVU4QCd-M{C5PFE2Pzh:L3G+
HEL	NX;QXHZlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3vVWVMh\GG7cx?=	NFywN2ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGVCClZXzsd{Bp[XKkb4LpcochUkGNMjDWOlE4TiCvdYThcpQhdWWjc4Xy[YQh[W[2ZYKgN{Bl[Xm\|IHL5JGNEUzhiYYPzZZktKEmFNUC9O{43OzoQvF2=	M4TIc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixOVc5Lz5\|MEm4NVU4QDxxYU6=
insect cells	M2LDS2Z2dmO2aX;uJIF{e2G7		MnrzNVAhdWmwcx?=	M1zZXWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzFiKEi2OkB1dyBzMUW0JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIF\JWGMudGGkZXzl[EBEPi2NS1jUSGRIYU2STWPQS3ZCNU6KIIDldJRq\GViYYOgd5Vje3S{YYTlJIFnfGW{IEGwJI1qdnNiaX6gdJJme2WwY3Wgc4YhPSCvTTDBWHAh[nliY3HsbZBmeiCvb3LpcIl1gSC\|aHnmeEBie3OjeTygTWM2OD1yLkCy{txO	NHfObGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkK5O\|c1Oyd-M{KyPVc4PDN:L3G+
insect cells	NIL5e49HfW6ldHnvckBie3OjeR?=		NHTySHMyOCCvaX7z	MY\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWszKCh6M{GgeI8hOTF\|MjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGmwc3XjeEBk\WyuczD1d4lv\yB3RlHNMYxi[mWuZXSgS2VGWEy\V2PGVGFMU0tvTliyJJBmeHSrZHWgZZMhe3Wkc4TyZZRmKGGodHXyJFExKG2rboOgbY4heHKnc3XuZ4Uhd2ZiNTDtUUBCXFBiYomgZ4FtcXCncjDtc4JqdGm2eTDzbIlnfCCjc4PhfUwhUUN3ME2wMlAz\|ryP	NFvNc\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkK5O\|c1Oyd-M{KyPVc4PDN:L3G+
BAF3	Mof4R5l1d3SxeHnjbZR6KGG\|c3H5		MWO0PEBpenN?	M{XWd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCMQVuyJHY3OTeIIH31eIFvfCCjZoTldkA1QCCqcoOgZpkhS2WubGTpeIVzT2yxIHHzd4F6NCCLQ{WwQVAvOTJ4zszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxO\|g6QTRzLze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Protocol

References

[1] Alfonso Quintás-Cardama, et al. Blood . 2010 Apr 15;115(15):3109-17.

Solubility (25°C)

In vitro	DMSO	80 mg/mL (197.84 mM)
	Water	29 mg/mL (71.71 mM)
	Ethanol	8 mg/mL (19.78 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	404.36
Formula	C₁₇H₁₈N₆.H₃O₄P
CAS No.	1092939-17-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	INCB018424, INC424
Smiles	C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02596347	Completed	Procedure: Blood draw\|Procedure: bronchoscopy	Chronic Beryllium Disease (CBD)\|Beryllium Sensitization (BeS)	National Jewish Health	April 2015	--
NCT01787552	Completed	Drug: LDE225\|Drug: INC424	Primary Myelofibrosis\|Thrombocytosis\|Essential Thrombocythemia\|Polycythemia Vera\|Myeloproliferative Disorders\|Bone Marrow Diseases\|Hematologic Diseases\|Blood Coagulation Disorders\|Blood Platelet Disorders\|Hemorrhagic Disorders	Novartis Pharmaceuticals\|Novartis	May 8 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

JAK Signaling Pathway Map

Related JAK Products

FLLL32 ^New

FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
Cerdulatinib (PRT062070) hydrochloride ^New

Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
Ruxolitinib (INCB018424)

Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
Tofacitinib (CP-690550) Citrate

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.
Tofacitinib (CP-690550)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.
Fedratinib (TG101348)

Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Momelotinib (CYT387)

Momelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) induces apoptosis and autophagy. Phase 3.
WP1066

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.

Features:Similar to its parent compound AG490, WP1066 inhibits the phosphorylation of JAK2, but unlike AG490, WP1066 also degraded JAK2 protein.

Choose Your Country or Region

By Signaling Pathways

By product type

Ruxolitinib Phosphate